Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B

DEXCOM INC

2024-Q2 EPS reported $0.71 revenue$1,925,300,000

Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.
GAAP EPS $0.35, Non-GAAP EPS $0.43; GAAP operating income $158.0M (15.7% margin).
FY2024 revenue guidance lowered to ~$4.00-4.05B (11-13% organic); Q3 rev guidance $975M-$1.00B.
Announces $750M share repurchase program authorized through June 30, 2025.
CEO Kevin Sayer acknowledges execution shortfall but cites long-term growth opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.